Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think.
Overview
Alnylam Pharmaceuticals (NASDAQ: ALNY) looks like an investor's nightmare at first glance. The drugmaker's shares have lost more than half their value over the past 12 months. The biotech stock is down more than 20% over the past four weeks.
Some Alnylam shareholders could be sorely tempted to throw in the towel. However, I think there's a strong case that the sell-off is way overdone. And I believe that many investors are missing a bigger story with Alnylam.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
- Walmart and Target are about to reveal the health of the U.S. consumer
- Strategy CEO Phong Le Thinks MSTR Stock Will Outperform Bitcoin During the Next Bull Market. Here's Why He's Wrong.
- The Stock Market Is on the Verge of Doing Something That No One's Witnessed in Nearly 156 Years, and the Consequences May Be Dire for Wall Street
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.